Mark Mugerditchian
Plus aucun poste en cours
Profil
Mr. Mark Mugerditchian is Vice President-Manufacturing at Laguna Pharmaceuticals, Inc.
Mr. Mugerditchian was previously employed as Senior Vice President-Manufacturing by NovaCardia, Inc., Senior Director-Manufacturing by Dura Pharmaceuticals, Inc., a Principal by Abbott Laboratories, Engineer by Fujisawa USA, Inc., Executive Director-Contract Manufacturing by Gensia Sicor Pharmaceuticals, Inc., Project Engineer by Key Pharmaceuticals, Inc., and Senior VP-Manufacturing & Product Development by Sequel Pharmaceuticals, Inc.
He received his undergraduate degree from the University of Illinois.
Anciens postes connus de Mark Mugerditchian
| Sociétés | Poste | Fin |
|---|---|---|
Dura Pharmaceuticals, Inc.
 Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA. | Corporate Officer/Principal | - |
Laguna Pharmaceuticals, Inc.
 Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Corporate Officer/Principal | - |
Fujisawa USA, Inc.
 Fujisawa USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Fujisawa Healthcare, Inc., Fujisawa USA, Inc. is a company based in Bannockburn, IL. | Corporate Officer/Principal | - |
Key Pharmaceuticals, Inc.
 Key Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Key Pharmaceuticals, Inc. operates as a subsidiary of Schering-Plough which is engaged in manufacturing, fabricating or processing drugs in pharmaceutical preparations. The company is located in Newark, NJ | Corporate Officer/Principal | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Formation de Mark Mugerditchian
| University of Illinois | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Entreprise privées | 7 |
|---|---|
NovaCardia, Inc.
 NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Health Technology |
Dura Pharmaceuticals, Inc.
Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA. | Health Technology |
| Gensia Sicor Pharmaceuticals, Inc. | |
Sequel Pharmaceuticals, Inc.
 Sequel Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA. | Retail Trade |
Key Pharmaceuticals, Inc.
Key Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Key Pharmaceuticals, Inc. operates as a subsidiary of Schering-Plough which is engaged in manufacturing, fabricating or processing drugs in pharmaceutical preparations. The company is located in Newark, NJ | Health Technology |
Fujisawa USA, Inc.
Fujisawa USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Fujisawa Healthcare, Inc., Fujisawa USA, Inc. is a company based in Bannockburn, IL. | Health Technology |
Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Health Technology |
